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a b s t r a c t
Severe combined immunodeficiency due to adenosine-deaminase defect (ADA-SCID) is usually deadly in
childhood because of severe recurrent infections. When clinical diagnosis is done, permanent damages
due to infections or metabolite accumulation are often present. Gene therapy, bone marrow transplanta-
tion or enzyme replacement therapy may be effective if started early. The aim of this study was to set-up
a robust method suitable for screening with a minimized preparation process and with inexpensive run-
ning costs, for diagnosing ADA-SCID by tandem mass spectrometry. ADA-SCID satisfies all the criteria for
inclusion in a newborn screening program.
We describe a protocol revised to incorporate adenosine and 2-deoxyadenosine testing into an
expanded newborn screening program. We assessed the effectiveness of this approach testing dried
blood spots from 4 genetically confirmed early-onset and 5 delayed-onset ADA-SCID patients. Refer-
ence values were established on 50,000 healthy newborns (deoxyadenosine <0.09 mol/L, adenosine
<1.61 mol/L). We also developed a second tier test to distinguish true positives from false positives and
improve the positive predictive value of an initial abnormal result.
In the first 18 months, the pilot project has identified a newborn with a genetically confirmed defect
in adenosine deaminase (ADA) gene.
The results show that the method having great simplicity, low cost and low process preparations can
be fully applicable to a mass screening program.. IntroductionSevere combined immunodeficiency due to a defect of adeno-
ine deaminase (ADA-SCID, OMIM # 102,700) is an inherited
isorder of purine metabolism [1] representing for approximately
Abbreviations: ADA-SCID, severe combined immunodeficiency due to
denosine-deaminase defect; SCID, severe combined immunodeficiency; ADA,
denosine deaminase; dAdo, 2-deoxyadenosine; ERT, enzyme replacement therapy;
do, adenosine; TRECs, T-cell receptor excision circles; DBS, dried blood spot; HPLC,
igh-performance liquid chromatography; RT, room temperature; LOD, limit of
etection; LLOQ, lower limit of quantitation; SUAC, succinylacetone; MRM, multiple
eaction monitoring; LC–MS/MS, liquid chromatography/tandem mass spectrome-
ry; MS, mass spectrometry.
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15% of all SCID cases and one-third of cases of autosomal reces-
sive SCID [2]. It is caused by mutation in the gene that encodes
a protein called adenosine deaminase (ADA, EC 3.5.4.4) [3]. Defi-
ciency of the purine salvage enzyme ADA results in varying degrees
of immunodeficiency, ranging from neonatal onset to late onset
immunodeficiency which can determine severe impairment of lung
function in adolescents or adults [4]. About 85–90% of patients
show an early severe SCID, that in the absence of treatment, leads
to death within the first year of life. Onset occurs between 6 months
and the first few years in 10–15% of patients with a ‘delayed’ clin-
ical manifestation and from second to fourth decades in a smaller
percentage of patients with ‘late’ onset, showing less severe infec-
tions and a slowly deteriorating immune function [5]. Finally, the
benign condition called ‘partial’ ADA deficiency is characterized by
a decreased enzyme activity in erythrocytes, but a residual enzyme
activity in leukocytes and other nucleated cells [6].
In the early onset form, the severe functional defect of the
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epresented primarily by 2-deoxyadenosine (dAdo) and dATP,
he phosphorylated end product of the ADA substrate dAdo
7]; on turn increased dAdo levels inactivate the enzyme S-
denosylhomocysteine hydrolase and result in inhibition of
ransmethylation of nucleic acids, proteins, and lipids [8].
Treatment options for ADA SCID are represented by stem-cell
ransplantation, enzyme replacement therapy (ERT) and gene ther-
py. Haematopoietic stem cell transplantation is today the gold
tandard treatment for ADA-SCID, although it is dependent on
good donor match [9]. ERT with polyethylene glycol-modified
ovine adenosine deaminase (PEG-ADA, Adagen®) is available and
etermines the elimination of toxic metabolites and a good recon-
titution of the immune system [10]. Gene therapy has also shown
romising results for some patients with ADA deficiency SCID [11].
In any case, an early treatment is mandatory to prevent ADA
CID symptoms and also to get the best therapeutic effect. For this
eason, diagnostic methods to make early diagnosis are important
o significantly improve patient health outcomes, while at the same
ime reducing the cost of medical care.
Diagnosis can be made detecting either ADA enzyme activity or
ccumulation of metabolites due to ADA deficiency.
Evaluating ADA activity is complex and sometimes can give mis-
eading results: actually a severe defect in ADA activity can be
ound in clinically unaffected subjects with a ‘partial’ ADA defi-
iency, because variable residual ADA activity expressed in cells
ifferent from immune cells can be sufficient to maintain good
mmune function [12,13]. Therefore measurement of metabolites
s absolutely mandatory to confirm the diagnosis of immunode-
ciency due to ADA deficiency. Moreover dosage of metabolites
llows monitoring the reduction of their levels after therapy. dAdo
nd adenosine (Ado) quantification are important in the diagnosis
f ADA SCID and their measurement in urine samples is per-
ormed in clinical practice by different methods, ranging from HPLC
o thin-layer chromatography, capillary electrophoresis and even
everse-phase HPLC with electrospray ionization tandem mass
pectrometry [14–17]. Anyway these methods are used when an
mmunodeficiency is suspected, generally when it’s too late to pre-
ent the damage and there is the risk of permanent disability.
Newborn screening for SCID based on measurement of T-cell
eceptor excision circles (TRECs), is able to identify all T lympho-
ytes defects, and was started in Wisconsin in 2008. It has been
dopted in part of the United States and in many countries around
he world since January 2010, when Secretary Advisory Committee
or Heritable Disorders in Newborns and Children recommended
he inclusion of SCID in the newborn screening panels [18].
Mass spectrometry is extensively used in newborn screening
rograms for analysis of metabolites from dried blood spots (DBS)
ollected a few days after birth, but among the detected metabolites
hose due to ADA deficiency have not been included so far [19,20].
Aim of the present work was to provide an analytical method
hat could allow the quantitation of ADA-SCID metabolites at the
ame time with the other metabolites that are commonly deter-
ined in expanded newborn screening programs.
. Materials and methods
.1. Standards and chemicals
Ado and dAdo were purchased from Sigma Aldrich (St. Louis,
O, USA); Adenosine-ribose-1-13C (13C, 99%) and deoxyadenosine-ibose-5-13C (13C, 98%) used as internal standards (IS) were
urchased from Cambridge Isotope Laboratories (Andover, MA,
SA). Stock solutions of Ado and dAdo chemical and labeled stan-
ard at 100 mol/L were prepared in HPLC grade water and storedd Biomedical Analysis 88 (2014) 201–206
at −20 ◦C. Working solutions were daily prepared from stock solu-
tions.
2.2. Newborn screening pilot project for ADA-SCID
Blood collection for expanded newborn screening by tan-
dem mass spectrometry (LC–MS/MS) in Tuscany is recommended
between 48 and 72 h of life. Blood samples are routinely obtained
by heel stick, spotted on filter paper (903®, Whatman GmbH, Dasel,
Germany), dried and sent by courier to the screening center.
The method was applied to 50,000 DBS from neonates born in
the period between January 2011 and June 2012 and data were used
to set up cut-off values. In the first 6 months of the pilot project,
DBS were processed in parallel by both the methods reported by la
Marca et al. [20] and the new screening method reported by Azzari
et al. [21] which is performed without butylation procedure and
with the addiction of Ado and dAdo IS, both at 1 mol/L for each
well.
Briefly, 200 L of methanolic solution of labeled acylcarnitines,
aminoacids, SUAC, Ado and dAdo were added to a 3.2 mm-paper
circle from the DBS (containing about 3.4 L of blood). 100 L of a
3 mmol/L solution of hydrazine in water was added to the mixture.
Mixture was put on an orbital shaker and kept at 37 ◦C. After 25 min,
the mixture was dried under N2 and reconstituted with 300 L of
a mixture of CH3CN 70% containing 0.1% of formic acid.
2.3. Second tier test
Calibrators were prepared by spotting 25 L of whole blood
from healthy adult blood donor on filter paper for the study of the
metabolite stability and for the repeatability tests.
DBSs were dried for a period of at the least 2 h at room tempera-
ture (RT) and were stored at 4 ◦C until analysis in sealed plastic bags
containing desiccant and a humidity indicator card. Whole blood
from healthy adult donors was collected after they gave informed
consent. All experiments were conducted in compliance with insti-
tutional review board guidelines (regional pilot project protocol n◦
7949/2011).
Calibrators were prepared at 0.1, 1, 10 and 100 mol/L of dAdo
and 0.2, 1, 10 and 100 mol/L of Ado as follows: a 3.2 mm disk
from a DBS was punched and extracted by dispensing 300 L of
a mixture of methanol and water (2:1, v/v) containing ribose-1-
13C-adenosine and 13C5 deoxyadenosine (10 mol/L) as internal
standard and different concentrations of Ado and dAdo. Calibra-
tors were shaken on a vortex system for 25 min at 37 ◦C and then
transferred to a 96-well plate.
3 L of each calibrator was injected into the mass spectrome-
ter for the MS/MS experiments. An Applied Biosystems/MDS Sciex
API 4000TM triple-quadrupole mass spectrometer equipped with a
TurboV-Spray® source with the turbo gas temperature set at 425 ◦C
was used to perform experiments. The source operates in positive
ionization polarity at a potential of +5500 V.
A Synergi® fusion RP column (150 mm × 2 mm i.d.; 4 m par-
ticle size) was used for the analysis. The mobile phase composed
of a mixture of 0.1% formic acid in water and 0.1% formic acid in
acetonitrile was applied in a constant ratio of 20:80 (v/v) at a flow
rate of 0.2 ml/min. Retention time of dAdo, Ado and their labeled
standards was 1.8 min. The analyte concentrations are calculated
automatically using the software Analyst Quantitate (ABI SCIEX,
Foster City, CA, USA).
The method was validated in terms of linearity, intra-day and
inter-day precision, accuracy by analyzing calibrators prepared as
above described. Intra-day precision data were evaluated by ten
replicate analysis of four different dAdo and Ado concentrations
on the same day. Inter-day precision data were determined by
the analysis of four different dAdo and Ado concentrations on 6















































Intra- and inter-day dAdo reproducibility on DBS assessed by %CV calculations.
Expected concentration (mol/L) Mean (n = 10) SD %CV Accuracy (%)
Intraday
0.10 0.09 0.01 8.10 90
1 0.90 0.05 5.53 90
10 10.21 0.39 3.85 102
100 99.95 5.96 5.96 99
Interday
0.10 0.09 0.01 13.97 90
1 1.18 0.05 4.36 115
10 10.99 0.32 2.91 109
100 106.41 0.60 0.57 106G. la Marca et al. / Journal of Pharmaceuti
ifferent days. Sensitivity was assessed by calculating the limit of
etection (LOD) and the lower limit of quantification (LLOQ). They
ere set by analyzing calibrators at 0, 0.05, 0.1, 0.2, 0.3, 0.5, 0.75, 1
nd 1.5 mol/L both for Ado and dAdo.
Isotope dilution-based quantization was performed by compar-
ng the extracted ion chromatogram (peak area) of the chemical
tandards and the one from the labeled standards.
.4. Patients
For the validation of this method, we retrospectively analyzed
ewborn screening cards from 4 genetically confirmed early onset
nd 5 delayed-onset ADA-SCID patients. Three were born in Tus-
any before ADA-SCID was included in the newborn screening
anel and six were from other screening laboratories. Clinical
nd genetics details on ADA-SCID patients and the correlation
f enzyme residual activity and metabolite’ levels have been
escribed by la Marca et al. [23].
. Results
.1. Newborn screening pilot project for ADA-SCID
The method described herein can be used to extract Ado
nd dAdo from a DBS sample under conditions that permit con-
urrently extracting other metabolites, such as succinylacetone
SUAC), amino acids, free carnitine, or acylcarnitines by the use of a
ixture of water and methanol. Therefore the test can be used in an
xpanded newborn screening program or during enzyme replace-
ent therapy to monitor the efficacy of therapy. The traditional
creening method was modified by adding labeled Ado and dAdo
s internal standards to the methanolic solution of labeled acylcar-
itines, amino acids and SUAC.
Mass spectral data for Ado and dAdo were obtained by a Multiple
eaction Monitoring (MRM). Specific MRM transitions for Ado and
ibose-1-13C-adenosine (268.2 > 136.1 and 269.2 > 136.1, respec-
ively), and for dAdo, ribose-5-13C deoxyadenosine, (respectively
52.2 > 136.1 and 257.2 > 136.1) were recorded.
Purines are not soluble in pure methanol; the experimental min-
mum percentage (v/v %) of water in the extracting mixture must
e 20%; 35–40% would gives the best results for purines extraction.
he presence of hydrazine water solution in the reported extrac-
ion procedure (see Section 2) at 33% (v/v) is the best compromise
o obtain an optimal extraction yield of both purines and all the
ther metabolites routinely tested.
The well plate routinely prepared contained a blank filter paper
unch and a positive DBS control containing Ado and dAdo at
nown concentration.
During the screening analysis, the concentration of each analyte
as determined through comparison with the internal standard
ollowed by subtraction of the blank value. Validation parameters
re reported in literature [21,22].The new test was applied to more than 50,000 DBS samples from
ewborns. Table 1 shows cut-off values for Ado and dAdo used for
he expanded newborn screening program. No differences between
ull-term or premature infants were detected. Positive rate at the
able 1





Lower cut off (−4SD) 0.00 0.00
Upper cut off (+4SD) 0.09 1.61first screening test was 0.02% (10:50,000 live births); 90% of them
(9/10) normalized at the 2nd tier test.
We performed retrospective analysis of newborn screening
cards from 9 truly positive ADA-SCID patients. All the tested
patients were confirmed positive by the test.
An ADA deficient patient, born in Tuscany in 2011, was identified
throughout newborn screening pilot project.
Fig. 1 shows the comparison between spectra from an ADA
patient and a healthy control.
3.2. Second tier test
Since the inclusion of ADA metabolites in the panel of new-
born screening showed some false positives, the development of
a second tier test has proved essential to cope the possibility of dis-
tinguish true positives from false positives and improve the positive
predictive value of an initial abnormal result.
The method was validated, by the use of calibrators at known
concentration of ADA metabolites chemical standards, in terms
of linearity, intra-day and inter-day precision and accuracy.
Calibrators, containing internal standard at 10 mol/L, were at con-
centrations of 0.1, 1, 10 and 100 mol/L for dAdo and at 0.2, 1, 10
and 100 mol/L for Ado.
Adenosine deaminase is present into the cells as well as on mem-
branes and it catalyzes the irreversible deamination of Ado and
dAdo to inosine and deoxyinosine. For this reason standards were
not added to the whole blood to prevent ADA metabolism. Calibra-
tors, prepared using a pooled whole blood obtained from healthy
donors spotted on filter paper, were extracted as above described.
The extracts were enriched of different Ado, dAdo and their inter-
nal standard concentrations and were analyzed to test validation
parameters.
When real samples from patients were analyzed, methanol
based solution deposition was first performed on DBS to prevent
enzyme reactivation, then water was used to extract purines.
During the sample preparation procedure, the first step con-
sisted of methanol addition to fix proteins on paper followed by
water addiction to extract purines.
The assays were linear up to 100 mol/L for both metabolites.
Intra- and interday imprecision data are reported in Tables 2 and 3.
LOD was 0.05 mol/L for dAdo and Ado and LLOQ was 0.1 mol/L
for dAdo and 0.2 mol/L for Ado.
In order to establish normal ranges for Ado and dAdo, 250
blood spots, reported as normal during newborn screening by
LC–MS/MS, were tested. The reference ranges for the 2nd tier test
were <0.1 mol/L for dAdo and 0.1–2 mol/L for Ado.
We measured ADA metabolites retrospectively in newborn
screening samples of 9 truly positive ADA-SCID patients to assess
whether 2nd tier testing could be effective. All the truly positive
patients showed ADA metabolites values out of ranges.
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Fig. 1. MRM experiments show dAdo is not present in a control w
Table 3
Intra- and inter-day Ado reproducibility on DBS assessed by %CV calculations.
Expected concentration (mol/L) Mean (n = 10) SD %CV Accuracy (%)
Intraday
0.20 0.19 0.03 16.7 95
1 1.15 0.06 4.9 115
10 10.37 0.56 5.4 104
100 99.86 8.07 8.1 100
Interday










1 1.08 0.02 2.09 108
10 10.46 0.10 0.93 105
100 100.22 0.73 0.73 100
During the newborn screening project 10 spots with abnormal
alues of dAdo were analyzed by the 2nd tier test. Among them,
were found to be false positive and one presented values over
ormal limits. A second DBS from this newborn was tested and
ositive results were confirmed. Application of this assay improved
he positive predictive value up to 100%. No false negative results
ave been reported at the moment.A flow chart used in the pilot screening program for ADA-SCID
as developed to apply this method as an efficient and effective
econd-tier assay on samples with abnormal results by primary
creening (Fig. 2).hereas increased levels are observed in a ADA-SCID patient.
4. Discussion and conclusions
Up to now, many newborn screening programs worldwide use
TRECs from DNA of exhausted DBS as method to evaluate ADA-SCID.
Unfortunately, this approach is expensive, it takes a long time and
it lacks of sensitivity in diagnosis of late and delayed onset ADA
SCID [21,24].
The proposed method can be used to simultaneously extract
and quantify Ado and dAdo, amino acids, acylcarnitines and
SUAC using LC–MS/MS. Therefore, the inclusion of this test into
the expanded newborn screening for inherited metabolic dis-
eases is possible. Considering that no extra operator time was
necessary for sample preparation or analysis beside the time nec-
essary for routine neonatal screening, no extra-equipment was
necessary and the instruments were not used for longer times,
the cost of the test was calculated for reagents only; including
unavoidable reagent waste it was valuable in about D 0.01 per
test.
Some procedures for newborn screening utilize derivatization
to form butyl esters and acidified butanol (3 N HCl in n-butanol) is
added to the extracted DBS in order to improve sensitivity. ADA-
SCID inclusion into the newborn screening panel is not compatible
with esterification because decreasing the pH leads to degradation
of ADA metabolites.


































Fig. 2. Flow chart used in the p
As an alternative to the proposed underivatized method, a two
tep procedure could be hypothesized: first step by using methanol
s extraction solution for aminoacids and acylcarnitines followed
y butilation; second step by using hydrazine solution for SUAC
nd purines. After evaporation procedure the two reconstituted
olutions could be reunified.
Our results show that ADA-SCID can be diagnosed with highest
ensitivity and specificity from DBS taken at birth. dAdo is consid-
red the most important marker for ADA-SCID while Ado is the
econdary marker.
No extra equipment or time is required beside the time neces-
ary for routine neonatal screening, therefore no additional costs
re required for applying such testing. The method is reliable and
eproducible, easy to perform and gives a definitive response within
short time.
Moreover an LC–MS/MS based second-tier test was set up in
rder to reduce false-positive results, which produce unnecessary
amily anxiety and increase follow-up costs.
Of the 50,000 newborns screened in the first 18 months pilot
roject, a full-term healthy newborn revealed abnormal levels of
oth Ado (6.9 mol/L) and dAdo (1.2 mol/L).
After positive 2nd tier test result, the newborn was recalled and
he confirmatory procedure started.
We were able to confirm that urinary Ado and dAdo levels were
ncreased in the proband using a previously described method
17]. ADA enzymatic activity, immunoglobulin levels, lymphocyte
ubsets and proliferation as well as ADA gene sequence were
erformed. Data obtained from all the biochemical and molecu-
ar analysis let to include our first patient as possible late onset
DA–SCID [23].
Identification of late onset ADA-SCID disease in newborns may
e stressful to the patients and their families; however, the ability
o monitor the patients and to perform a correct therapy reduce the
isk that irreversible damages occur.
Up to now no later onset ADA-SCID patients have been identified
t birth, so no data are present in literature on the natural history
f a later phenotype [23]. The present method offers, for the first
ime, the possibility to get the diagnosis of ADA-SCID at birth, before
nset of infectious disease. Therefore, this project also increased our
nowledge about the delayed and late manifestation of ADA-SCID
isease in young infants.reening program for ADA-SCID.
Early diagnosis of SCID allows treating the affected patients very
soon so avoiding severe complications due to infectious disease
which are always expected in the follow-up of immunodeficient
patients [22].
Considering that at the moment the most part of laboratories
performing expanded newborn screening by tandem mass spec-
trometry are not yet equipped for molecular biology analyses, the
present approach has to be considered as a good option to the vali-
dated TREC test. Moreover, delayed ADA-SCID false negative cases
by TREC test have been recently described [23–25]
Within the last 7 years (2004–2011) approximately 250,000
births occurred in Tuscany, among them four ADA-SCID patients
were diagnosed. These preliminary data show the incidence in
our catchment area seems to be greater than about 1:500,000 as
reported in literature [26].
The proposed method is able to quantify dAdo and Ado dur-
ing newborn screening; 2nd tier test, as described, reduces recall
rate close to zero. In addition, DBS collection has several advan-
tages compared to other frozen specimens including lower cost and
easy sample storage and transport. The use of DBS can be a con-
venient alternative to urines or plasma to make diagnosis of ADA
SCID but also to simplify therapy monitoring in patients undergo-
ing bone marrow transplantation, enzyme replacement therapy or
gene therapy.
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